SIP Trunking News

TMCNet:  SORRENTO THERAPEUTICS, INC. FILES (8-K) Disclosing Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits

[May 30, 2014]

SORRENTO THERAPEUTICS, INC. FILES (8-K) Disclosing Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits

(Edgar Glimpses Via Acquire Media NewsEdge) Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 23, 2014, Sorrento Therapeutics, Inc. ("Sorrento" or the "Company") promoted Mike Royal to Executive Vice President of Clinical and Regulatory Affairs.

Dr. Royal joined Sorrento in March 2014 as a Senior Vice President of Clinical Development. Dr. Royal brings more than 20 years of drug development experience where he was a key contributor to over a dozen ANDAs and several NDAs, most recently Zalviso™ at AcelRx and Ofirmev® at Cadence (currently being acquired by Mallinckrodt). He has managed clinical operations and regulatory activities across multiple trials and multiple countries for both small molecule and biologic products. He is board certified in internal medicine, pain medicine, anesthesiology with additional certification in pain management, addiction medicine, and legal medicine. He has authored or co-authored more than 170 papers and abstracts. Previously, he was a clinical adjunct professor at the University of California San Diego and the University of Oklahoma Medical School, and a faculty member at the University of Pittsburgh Medical Center. He has also worked at Elan, Alpharma and Solstice Neuroscience. He graduated from the Massachusetts Institute of Technology in synthetic organic chemistry. He earned his M.D. from the Massachusetts Medical School, law degree from the University of Maryland School of Law, and MBA from TRIUM (NYU-Stern, HEC-Pairs and the London School of Economics).


On May 23, 2014, Dr. Vuong Trieu resigned as Chief Scientific Officer of the Company. Dr. Trieu will remain with the Company as a director.

Item 8.01 Other Events.

On May 30, 2014, the Company issued a press release announcing that Henry Ji, Ph.D., President and Chief Executive Officer of Sorrento, will present at the Jefferies 2014 Global Healthcare Conference. The Company's press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in this Item 8.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any registration statement filed under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference therein.

-------------------------------------------------------------------------------- Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description 99.1 Press Release dated May 30, 2014 --------------------------------------------------------------------------------

[ Back To SIP Trunking Home's Homepage ]